You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
By screening swine samples at thousands of European farms, researchers saw reassorted versions of the 2009 H1N1 swine flu virus that may be able to dodge human immunity.
The acquisition will give Curi access to Dana's portfolio of artificial intelligence and machine learning technologies for in vitro cell-based assays.
The Emeryville, California-based instrument maker expects to raise $178.2 million after offering 8.1 million shares at $22 per share.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.
Axxam said it will use the CRISPR technology to support the development of customized cell-based assays for targets and molecular pathways of interest.
UK-based Abcam has acquired Oregon-based life science research tool provider Marker Gene Technologies, the latest in a string of asset purchases.
Microbiome and immune features in the mouths of e-cigarette smokers, cigarette smokers, and controls revealed a rise in periodontal disease-related bugs and inflammation in vape users.
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.